This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CTI Appoints Monique Greer, Senior Vice President, Corporate Communications And Investor Relations

SEATTLE, Nov. 12, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, announced today the appointment of Monique Greer as Senior Vice President, Corporate Communications and Investor Relations.  Ms. Greer will be responsible for leading CTI's external and internal communications strategies and will report directly to James A. Bianco, M.D., President and Chief Executive Officer.

"Monique is a key hire to drive consistent communications globally, as we transition from a product development organization to a commercial organization," said James Bianco.  "She has an excellent reputation in the biotechnology industry for developing and executing strategic, results-driven communications programs that advance business objectives.  We believe Monique's recent hematology/oncology commercial experience, management discipline and entrepreneurial drive will serve CTI well as we execute on our global strategy to deliver results for both patients and shareholders."

Ms. Greer has more than 17 years' experience planning and implementing strategic biotech/healthcare corporate communications, investor and media relations, and advocacy relations programs in support of product development, commercialization and strategic initiatives.  Most recently, Ms. Greer was Vice President of Corporate Communications and Investor Relations for Allos Therapeutics, Inc. (recently acquired by Spectrum Pharmaceuticals).  Ms. Greer served previously as Senior Associate in the Corporate Communications and Investor Relations practice for WCG, a global communications agency, where she created and implemented integrated, strategic communications programs for the firm's clients in the United States and Europe.  She has also served as Senior Director, Corporate Communications and Investor Relations for Dendreon Corporation, as well as Director, Corporate Communications for Heska Corporation.  Ms. Greer received a bachelor of science in Business Administration from Northeastern University.

About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

Contact: Ed BellT: 206.282.7100F: 206.272.4434E: invest@ctiseattle.com www.CellTherapeutics.com/investors

SOURCE Cell Therapeutics, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs